{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T09:46:26Z","timestamp":1776505586419,"version":"3.51.2"},"reference-count":125,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Future Med. Chem."],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.4155\/fmc.12.34","type":"journal-article","created":{"date-parts":[[2012,4,24]],"date-time":"2012-04-24T17:38:57Z","timestamp":1335289137000},"page":"751-769","source":"Crossref","is-referenced-by-count":14,"title":["PBEF\/NAMPT\/Visfatin: A Promising Drug Target For Treating Rheumatoid Arthritis?"],"prefix":"10.1080","volume":"4","author":[{"given":"Mari","family":"Nowell","sequence":"first","affiliation":[{"name":"Institute of Infection &amp; Immunity, School of Medicine, Cardiff University, Cardiff, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Evans","sequence":"additional","affiliation":[{"name":"Institute of Infection &amp; Immunity, School of Medicine, Cardiff University, Cardiff, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anwen","family":"Williams","sequence":"additional","affiliation":[{"name":"Institute of Infection &amp; Immunity, School of Medicine, Cardiff University, Cardiff, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2012,4,24]]},"reference":[{"issue":"2","key":"e_1_3_2_3_1_1","first-page":"1431","article-title":"Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor.","volume":"14","author":"Samal B","year":"1994","unstructured":"Samal B , SunY, StearnsG, XieC, SuggsS, McNieceI. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor.Mol. Cell. Biol.14(2), 1431\u20131437 (1994).","journal-title":"Mol. Cell. Biol."},{"key":"e_1_3_2_3_2_1","doi-asserted-by":"publisher","DOI":"10.1128\/JB.183.4.1168-1174.2001"},{"key":"e_1_3_2_3_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200211)32:11<3225::AID-IMMU3225>3.0.CO;2-L"},{"key":"e_1_3_2_3_4_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1097243"},{"key":"e_1_3_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M805866200"},{"key":"e_1_3_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.3.1748"},{"key":"e_1_3_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12013-008-9041-4"},{"key":"e_1_3_2_3_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2008.10.004"},{"key":"e_1_3_2_3_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/332454a0"},{"key":"e_1_3_2_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)49791-3"},{"key":"e_1_3_2_3_11_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.7.3268"},{"key":"e_1_3_2_3_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/17.13.3534"},{"key":"e_1_3_2_3_13_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.nutr.28.061807.155443"},{"key":"e_1_3_2_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2006.11.006"},{"key":"e_1_3_2_3_15_1","doi-asserted-by":"publisher","DOI":"10.1089\/jir.1986.6.267"},{"key":"e_1_3_2_3_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21942"},{"key":"e_1_3_2_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-5890(01)00097-9"},{"key":"e_1_3_2_3_18_1","doi-asserted-by":"publisher","DOI":"10.1677\/jme.0.0260107"},{"key":"e_1_3_2_3_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(00)70490-X"},{"key":"e_1_3_2_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2006.06.052"},{"key":"e_1_3_2_3_21_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1170803"},{"key":"e_1_3_2_3_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.07.035"},{"key":"e_1_3_2_3_23_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M506162200"},{"key":"e_1_3_2_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.devcel.2008.02.004"},{"key":"e_1_3_2_3_25_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000173298.38808.27"},{"key":"e_1_3_2_3_26_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.7.4685"},{"key":"e_1_3_2_3_27_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M408388200"},{"key":"e_1_3_2_3_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5699(99)01552-2"},{"key":"e_1_3_2_3_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2007.07.007"},{"key":"e_1_3_2_3_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0962-8924(02)02342-5"},{"key":"e_1_3_2_3_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.148957"},{"key":"e_1_3_2_3_32_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901467"},{"key":"e_1_3_2_3_33_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M803196200"},{"key":"e_1_3_2_3_34_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.219832"},{"key":"e_1_3_2_3_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1906"},{"key":"e_1_3_2_3_36_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007897"},{"key":"e_1_3_2_3_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1913"},{"key":"e_1_3_2_3_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2007.09.003"},{"key":"e_1_3_2_3_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-010-2042-z"},{"key":"e_1_3_2_3_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22833"},{"key":"e_1_3_2_3_41_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.10.2911"},{"key":"e_1_3_2_3_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0b013e32801b3c8f"},{"key":"e_1_3_2_3_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-006-0173-z"},{"key":"e_1_3_2_3_44_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI19930"},{"key":"e_1_3_2_3_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2006.11.014"},{"key":"e_1_3_2_3_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2009.11.066"},{"key":"e_1_3_2_3_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2007.05.096"},{"key":"e_1_3_2_3_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2007.09.019"},{"key":"e_1_3_2_3_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24416"},{"key":"e_1_3_2_3_50_1","doi-asserted-by":"publisher","DOI":"10.1177\/0961203309103582"},{"key":"e_1_3_2_3_51_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200404-563OC"},{"key":"e_1_3_2_3_52_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2006.11.021"},{"key":"e_1_3_2_3_53_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.046540"},{"key":"e_1_3_2_3_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2009.02085.x"},{"key":"e_1_3_2_3_55_1","doi-asserted-by":"publisher","DOI":"10.1515\/JPM.2008.084"},{"key":"e_1_3_2_3_56_1","doi-asserted-by":"publisher","DOI":"10.2337\/db08-1176"},{"key":"e_1_3_2_3_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24626"},{"key":"e_1_3_2_3_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2011.04.004"},{"issue":"1","key":"e_1_3_2_3_59_1","first-page":"56","article-title":"Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-alpha therapy.","volume":"28","author":"Gonzalez-Gay MA","year":"2010","unstructured":"Gonzalez-Gay MA , Vazquez-RodriguezTR, Garcia-UnzuetaMTet al. Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-alpha therapy. Clin. Exp. Rheumatol. 28(1), 56\u201362 (2010).","journal-title":"Clin. Exp. Rheumatol."},{"key":"e_1_3_2_3_60_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.077578"},{"key":"e_1_3_2_3_61_1","doi-asserted-by":"publisher","DOI":"10.1186\/1755-8794-3-15"},{"key":"e_1_3_2_3_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2006.02.109"},{"key":"e_1_3_2_3_63_1","doi-asserted-by":"publisher","DOI":"10.1177\/1753425911428553"},{"key":"e_1_3_2_3_64_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.665893"},{"key":"e_1_3_2_3_65_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-1475"},{"key":"e_1_3_2_3_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0463.2011.02733.x"},{"issue":"5","key":"e_1_3_2_3_67_1","first-page":"522","article-title":"Over-expression of nicotinamide phosphoribosyltransferase in ovarian cancers.","volume":"3","author":"Shackelford RE","year":"2010","unstructured":"Shackelford RE , BuiMM, CoppolaD, HakamA. Over-expression of nicotinamide phosphoribosyltransferase in ovarian cancers.Int. J. Clin. Exp. Pathol.3(5), 522\u2013527 (2010).","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"e_1_3_2_3_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(99)01578-1"},{"key":"e_1_3_2_3_69_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-0936"},{"key":"e_1_3_2_3_70_1","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2002.126295"},{"key":"e_1_3_2_3_71_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-010-1649-2"},{"key":"e_1_3_2_3_72_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080503"},{"issue":"4","key":"e_1_3_2_3_73_1","first-page":"628","article-title":"El Bakri S, ElZaher A, Abo-Shady R. Pre-B Cell Colony-enhancing factor as a marker of erosions in rheumatoid arthritis patients","volume":"8","author":"Zifzaf D","year":"2011","unstructured":"Zifzaf D , KaddahE, El Bakri S, ElZaher A, Abo-Shady R. Pre-B Cell Colony-enhancing factor as a marker of erosions in rheumatoid arthritis patients. Life Sci. J.8(4), 628\u2013634 (2011).","journal-title":"Life Sci. J."},{"key":"e_1_3_2_3_74_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30338"},{"key":"e_1_3_2_3_75_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23431"},{"key":"e_1_3_2_3_76_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3705"},{"key":"e_1_3_2_3_77_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.480"},{"key":"e_1_3_2_3_78_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2011-1128"},{"key":"e_1_3_2_3_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(01)00194-7"},{"key":"e_1_3_2_3_80_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003706"},{"key":"e_1_3_2_3_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrfmmm.2009.06.012"},{"key":"e_1_3_2_3_82_1","unstructured":"Fox EJ GibsonM ZhangLQ LeederJS YeSQ BeckerML. Decreased Expression of nicotinamide phosphoribosyltransferase (NAMPT) in active juvenile idiopathic arthritis patients receiving methotrexate. Presented at: American College of Rheumatology\/Association of Rheumatology Health Professionals Annual Scientific Meeting. Chicago IL USA 4\u20139 November 2011."},{"key":"e_1_3_2_3_83_1","unstructured":"Herenius M KlaasenR de Jager W Prakken BJ Gerlag D Tak PP. Anti-TNF therapy reduces adipocytokine levels and improves the lipid profile in patients with rheumatoid arthritis: a possible mechanism contributing to lowered cardiovascular risk. Presented at: American College of Rheumatology\/Association of Rheumatology Health Professionals Annual Scientific Meeting. Atlanta GA USA 6\u201311 November 2010."},{"key":"e_1_3_2_3_84_1","first-page":"235","article-title":"Treatment of arthritis by nicotinic acid and nicotinamide.","volume":"81","author":"Hoffer A","year":"1959","unstructured":"Hoffer A . Treatment of arthritis by nicotinic acid and nicotinamide.Can. Med. Assoc. J.81, 235\u2013238 (1959).","journal-title":"Can. Med. Assoc. J."},{"key":"e_1_3_2_3_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/0167-8140(92)90193-X"},{"issue":"4","key":"e_1_3_2_3_86_1","first-page":"1057","article-title":"WK175, a novel anti-tumor agent, decreases the intracellular nicotinamide adenine dinucleotide concentration and induces the apoptotic cascade in human leukemia cells.","volume":"62","author":"Wosikowski K","year":"2002","unstructured":"Wosikowski K , MatternK, SchemaindaI, HasmannM, RattelB, LoserR. WK175, a novel anti-tumor agent, decreases the intracellular nicotinamide adenine dinucleotide concentration and induces the apoptotic cascade in human leukemia cells.Cancer Res.62(4), 1057\u20131062 (2002).","journal-title":"Cancer Res."},{"issue":"21","key":"e_1_3_2_3_87_1","first-page":"7436","article-title":"FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis.","volume":"63","author":"Hasmann M","year":"2003","unstructured":"Hasmann M , SchemaindaI. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis.Cancer Res.63(21), 7436\u20137442 (2003).","journal-title":"Cancer Res."},{"issue":"6","key":"e_1_3_2_3_88_1","first-page":"4853","article-title":"Antiangiogenic potency of FK866\/K22.175, a new inhibitor of intracellular NAD biosynthesis, in murine renal cell carcinoma.","volume":"23","author":"Drevs J","year":"2003","unstructured":"Drevs J , LoserR, RattelB, EsserN. Antiangiogenic potency of FK866\/K22.175, a new inhibitor of intracellular NAD biosynthesis, in murine renal cell carcinoma.Anticancer Res.23(6C), 4853\u20134858 (2003).","journal-title":"Anticancer Res."},{"key":"e_1_3_2_3_89_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1399"},{"key":"e_1_3_2_3_90_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-007-9083-2"},{"key":"e_1_3_2_3_91_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30338"},{"key":"e_1_3_2_3_92_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002267"},{"key":"e_1_3_2_3_93_1","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb1105"},{"key":"e_1_3_2_3_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2006.06.082"},{"key":"e_1_3_2_3_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2005.05.016"},{"key":"e_1_3_2_3_96_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3176"},{"issue":"9","key":"e_1_3_2_3_97_1","first-page":"2843","article-title":"A Phase I study of CHS 828 in patients with solid tumor malignancy.","volume":"8","author":"Hovstadius P","year":"2002","unstructured":"Hovstadius P , LarssonR, JonssonEet al. A Phase I study of CHS 828 in patients with solid tumor malignancy. Clin. Cancer Res. 8(9), 2843\u20132850 (2002).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_2_3_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.12.023"},{"key":"e_1_3_2_3_99_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-009-1125-3"},{"key":"e_1_3_2_3_100_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-09-1130"},{"issue":"22","key":"e_1_3_2_3_101_1","first-page":"5751","article-title":"CHS 828, a novel pyridyl cyanoguanidine with potent anti-tumor activity in vitro and in vivo.","volume":"59","author":"Hjarnaa PJ","year":"1999","unstructured":"Hjarnaa PJ , JonssonE, LatiniSet al. CHS 828, a novel pyridyl cyanoguanidine with potent anti-tumor activity in vitro and in vivo. Cancer Res. 59(22), 5751\u20135757 (1999).","journal-title":"Cancer Res."},{"key":"e_1_3_2_3_102_1","unstructured":"Fleischer TC BaichwalVR BonifaceJJet al. Coadministration of nicotinic acid with the Nampt inhibitor MPC-9528 enhances anti-tumor activity in Naprt deficient cancer cells in culture and in xenografts. Presented at: AACR 102nd Annual Meeting. Orlando FL USA 2\u20136 April 2011."},{"key":"e_1_3_2_3_103_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.200700311"},{"key":"e_1_3_2_3_104_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10059-009-0088-x"},{"key":"e_1_3_2_3_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2011.01.034"},{"key":"e_1_3_2_3_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(97)10152-4"},{"issue":"22","key":"e_1_3_2_3_107_1","first-page":"5751","volume":"59","author":"Vig Hjarnaa P","year":"1999","unstructured":"Vig Hjarnaa P -J, Jonsson E, Latini S et al. CHS 828, a novel pyridyl cyanoguanidine with potent anti-tumor activity in vitro and in vivo. Cancer Res.59(22), 5751\u20135757 (1999).","journal-title":"Cancer Res."},{"key":"e_1_3_2_3_108_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3835(00)00661-3"},{"key":"e_1_3_2_3_109_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200111000-00005"},{"key":"e_1_3_2_3_110_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00112-09"},{"key":"e_1_3_2_3_111_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25206"},{"key":"e_1_3_2_3_112_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0320(19980901)33:1<56::AID-CYTO7>3.0.CO;2-9"},{"key":"e_1_3_2_3_113_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690270"},{"key":"e_1_3_2_3_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2010.05.008"},{"key":"e_1_3_2_3_115_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm101145b"},{"key":"e_1_3_2_3_116_1","unstructured":"Fleischer TC BaichwalVR BradfordCLet al. MPI-0486348: A novel inhibitor of nicotinamide phosphoribosyltransferase induces tumor regression in a preclinical model. Presented at: AACR 101st Annual Meeting. Washington DC USA 17\u201321 April 2010."},{"key":"e_1_3_2_3_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2010.12.035"},{"key":"e_1_3_2_3_118_1","doi-asserted-by":"publisher","DOI":"10.1080\/01635580903191585"},{"key":"e_1_3_2_3_119_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-677"},{"key":"e_1_3_2_3_120_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken163"},{"key":"e_1_3_2_3_121_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2007.03335.x"},{"key":"e_1_3_2_3_122_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704870"},{"key":"e_1_3_2_3_123_1","unstructured":"Fleischer TC FlickJS Terry-LorenzoRTet al. Identifying the target of an orphan compound: CB30865 is a Nampt inhibitor. Presented at: AACR 101st Annual Meeting. Washington DC USA 17\u201321 April 2010."},{"key":"e_1_3_2_3_124_1","unstructured":"Boniface JJ BaichwalVR CimboraDMet al. Basal NAD levels and Nampt expression correlate with in vitro and in vivo sensitivity of tumor cell lines to the Nampt inhibitor MPC09528. Presented at: AACR 102nd Annual Meeting. Orlando FL USA 2\u20136 April 2011."},{"key":"e_1_3_2_3_125_1","unstructured":"Carlson RO WillardsenJA LockmanJWet al. Pharmacokinetics anti-tumor activity and therapeutic index of Nampt inhibitor MPC-8640 in mice. Presented at: AACR-NCI-EORTC International Conference. San Francisco CA USA 12\u201316 November 2011."}],"container-title":["Future Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.4155\/fmc.12.34","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T19:51:18Z","timestamp":1716493878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.4155\/fmc.12.34"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":125,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["10.4155\/fmc.12.34"],"URL":"https:\/\/doi.org\/10.4155\/fmc.12.34","relation":{},"ISSN":["1756-8919","1756-8927"],"issn-type":[{"value":"1756-8919","type":"print"},{"value":"1756-8927","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}